Patent(s) and the Corresponding Patented Drug(s) |
Top |
World Intellectual Property Organization (WIPO) |
Patent ID |
WO2016089804 |
Title |
Inhibitors of Ezh2. |
Abstract |
The present invention relates to compounds that inhibit activity of the histone lysine N-methyltransferase, Enhancer of Zeste Homolog 2 (EZH2), pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, such as hematologic and solid tumors. |
Applicant(s) |
Eli Lilly and Company |
Representative Drug(s) |
D01PZZ |
Drug Info
|
IC50 = 0.93 nM |
Click to Show More |
[1] |
2
|
D0G1JR
|
Drug Info
|
IC50 = 6.45 nM
|
[1] |
Patent ID |
WO2016066697 |
Title |
Enhancer of Zeste Homolog 2 Inhibitors. |
Abstract |
This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homo log 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers. |
Applicant(s) |
Glaxosmithkline Intellectual Property (No.2) Limited |
Representative Drug(s) |
D0FI3A |
Drug Info
|
IC50 = 20 nM |
Click to Show More |
[1] |
2
|
D03MYI
|
Drug Info
|
IC50 = 100 nM
|
[1] |
3
|
D0Z7GN
|
Drug Info
|
IC50 = 100 nM
|
[1] |
4
|
D0RD5P
|
Drug Info
|
IC50 = 316 nM
|
[1] |
5
|
D0M1TG
|
Drug Info
|
IC50 = 500 nM
|
[1] |
Patent ID |
WO2015200650 |
Title |
Substituted Benzene and 6,5-Fused Bicyclic Heteroaryl Compounds. |
Abstract |
The present invention relates to substituted benzene compounds and bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes. |
Applicant(s) |
Epizyme, Inc |
Representative Drug(s) |
D08MXO |
Drug Info
|
IC50 < 1000 nM |
Click to Show More |
[1] |
2
|
D09GFF
|
Drug Info
|
IC50 < 1000 nM
|
[1] |
3
|
D09PQQ
|
Drug Info
|
IC50 < 1000 nM
|
[1] |
4
|
D0M9BY
|
Drug Info
|
IC50 < 1000 nM
|
[1] |
5
|
D0Z0NC
|
Drug Info
|
IC50 < 1000 nM
|
[1] |
Patent ID |
WO2015193768 |
Title |
Aryl Fused Lactams As Ezh2 Modulators. |
Abstract |
This invention relates to compounds of Formula (I) in which R1, R2, R3, R4, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer. |
Applicant(s) |
Pfizer Inc |
Representative Drug(s) |
D0B4TX |
Drug Info
|
IC50 = 2 nM; Ki < 1 nM |
Click to Show More |
[1] |
2
|
D0D4UH
|
Drug Info
|
IC50 = 5 nM
|
[1] |
3
|
D0M8AA
|
Drug Info
|
IC50 = 168000 nM
|
[1] |
Patent ID |
WO2015010078 |
Title |
Substituted 6,5-Fused Bicyclic Heteroaryl Compounds. |
Abstract |
The present invention relates to substituted bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes. |
Applicant(s) |
Epizyme, Inc |
Representative Drug(s) |
D0TA4N |
Drug Info
|
IC50 = 1470 nM |
Click to Show More |
[1] |
2
|
D0GT7A
|
Drug Info
|
IC50 = 21900 nM
|
[1] |
Patent ID |
WO2015004618 |
Title |
Enhancer of Zeste Homolog 2 Inhibitors. |
Abstract |
This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers. |
Applicant(s) |
Glaxosmithkline Intellectual Property (No.2) Limited |
Representative Drug(s) |
D0MO2X |
Drug Info
|
IC50 = 16 nM |
Click to Show More |
[1] |
2
|
D0MH8G
|
Drug Info
|
IC50 = 100 nM
|
[1] |
Patent ID |
WO2015077193 |
Title |
Inhibitors of Lysine Methyl Transferase. |
Abstract |
There are disclosed compounds that are inhibitors of EZH2, pharmaceutical compositions containing said compounds and methods of treating hyperproliferative, inflammatory, infectious, and immunoregulatory disorders and diseases, utilizing the compounds of the invention. |
Applicant(s) |
Bristol-Myers Squibb Company |
Representative Drug(s) |
D0A0VH |
Drug Info
|
IC50 > 1 nM; IC50 < 2 nM; Ki > 0.01 nM; Ki < 0.04 nM |
Click to Show More |
[1] |
2
|
D0FC9J
|
Drug Info
|
IC50 > 1 nM; IC50 < 2 nM; Ki > 0.01 nM; Ki < 0.04 nM
|
[1] |
3
|
D0LR5O
|
Drug Info
|
IC50 > 1 nM; IC50 < 2 nM; Ki > 0.01 nM; Ki < 0.04 nM
|
[1] |
4
|
D0PB6T
|
Drug Info
|
IC50 > 1 nM; IC50 < 2 nM; Ki > 0.01 nM; Ki < 0.04 nM
|
[1] |
5
|
D0BT6Y
|
Drug Info
|
N.A.
|
[1] |
6
|
D0QH1J
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
WO2016073956 |
Title |
Ezh2 Inhibitors and Uses Thereof. |
Abstract |
The present disclosure provides compounds of any one of Formulae (I) and (II). The compounds described herein are inhibitors of histone methyltransferases (e.g., enhancer of zeste homolog 1 (EZH1) and enhancer of zeste homolog 2 (EZH2)) and are useful in treating and/or preventing a broad range of diseases (e.g., proliferative diseases). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein. Further provided in the present disclosure are methods of identifying EZH1and/or EZH2 inhibitors. |
Applicant(s) |
Dana-Farber Cancer Institute, Inc |
Representative Drug(s) |
D0CH4O |
Drug Info
|
IC50 = 80 nM |
Click to Show More |
[1] |
2
|
D07CZI
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
WO2015077194 |
Title |
Inhibitors of Lysine Methyl Transferase. |
Abstract |
There are disclosed compounds that are inhibitors of EZH2, pharmaceutical compositions containing said compounds and methods of treating hyperproliferative, inflammatory, infectious, and immunoregulatory disorders and diseases utilizing the compounds of the invention. |
Applicant(s) |
Bristol-Myers Squibb Company |
Representative Drug(s) |
D0H4HR |
Drug Info
|
N.A. |
Click to Show More |
[1] |
2
|
D0PI5O
|
Drug Info
|
N.A.
|
[1] |
3
|
D0U9OH
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
WO2015010049 |
Title |
Substituted Benzene Compounds. |
Abstract |
The present invention relates to substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes. |
Applicant(s) |
Epizyme, Inc |
Representative Drug(s) |
D0BL8W |
Drug Info
|
N.A. |
Click to Show More |
[1] |
2
|
D0KR2T
|
Drug Info
|
N.A.
|
[1] |
3
|
D0SQ1R
|
Drug Info
|
N.A.
|
[1] |
4
|
D0SY6P
|
Drug Info
|
N.A.
|
[1] |
5
|
D0T8QL
|
Drug Info
|
N.A.
|
[1] |
6
|
D0UG5O
|
Drug Info
|
N.A.
|
[1] |
7
|
D0VF0M
|
Drug Info
|
N.A.
|
[1] |
8
|
D0Z0QS
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
WO2014144747 |
Title |
Substituted 6,5-Fused Bicyclic Heteroaryl Compounds. |
Abstract |
The present invention relates to azole bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes. |
Applicant(s) |
Epizyme, Inc |
Representative Drug(s) |
D04PCW |
Drug Info
|
N.A. |
Click to Show More |
[1] |
2
|
D0R2TQ
|
Drug Info
|
N.A.
|
[1] |
3
|
D0W4MW
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
WO2014124418 |
Title |
Preparation of Methyloxodihydropyridinylmethylcarbamoylmethylindole Derivatives and Analogs for Use As Histone Methyl Modifying Enzyme Modulators. |
Representative Drug(s) |
D0D1QD |
Drug Info
|
N.A. |
Click to Show More |
[1] |
2
|
D0DQ6N
|
Drug Info
|
N.A.
|
[1] |
3
|
D0W2KL
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
WO2016102493 |
Title |
Imidazopyridine Ezh2 Inhibitors. |
Abstract |
The present invention relates to imidazopyridines of general formula (I), to a method for their preparation, to intermediates for their preparation, to pharmaceutical compositions comprising at least one of those compounds, and to the use thereof. |
Applicant(s) |
Bayer Pharma Aktiengesellschaft the Broad Institute Inc |
Representative Drug(s) |
D0M4LK |
Drug Info
|
IC50 = 8.13 nM |
[1] |
Patent ID |
WO2015132765 |
Title |
Enhancer of Zeste Homolog 2 Inhibitors. |
Abstract |
This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers. (I). |
Applicant(s) |
Glaxosmithkline Intellectual Property (No.2) Limited |
Representative Drug(s) |
D0S4OP |
Drug Info
|
IC50 = 32 nM |
[1] |
Patent ID |
WO2016130396 |
Title |
Modulators of Methyl Modifying Enzymes, Compositions and Uses Thereof. |
Abstract |
Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with methyl modifying enzymes. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with methyl modifying enzymes. |
Applicant(s) |
Constellation Pharmaceuticals, Inc |
Representative Drug(s) |
D0MZ8D |
Drug Info
|
N.A. |
[1] |
Patent ID |
WO2014193930 |
Title |
Method for Inhibiting Ezh2 Expression In Breast Cancer Cells. |
Abstract |
The present invention is directed to a method for inhibiting the overexpression of EZH2 in breast cancer cells. The method comprises administering to breast cancer cells an effective amount of YC-1 (3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole), YC-1-succinate (succinic acid mono-[5-(1-benzyl-1H-indazol-3-yl)-furan-2-ylmethyl] ester), or a pharmaceutically acceptable salt thereof. The present invention is also directed to treating breast cancer comprising administering to a subject an effective amount of YC-1-succinate. |
Applicant(s) |
Yung Shin Pharm. Ind. Co., Ltd |
Representative Drug(s) |
D0L1TA |
Drug Info
|
N.A. |
[2] |
United States Patent and Trademark Office (USPTO) |
Patent ID |
US20140107122 |
Title |
Preparation of Substituted Benzene Compounds As Anticancer Agents. |
Representative Drug(s) |
D0H8VN |
Drug Info
|
IC50 < 10 nM |
[1] |